Literature DB >> 22190427

Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients.

Alpesh N Amin1, Helen Varker, Nicole Princic, Jay Lin, Stephen Thompson, Stephen Johnston.   

Abstract

BACKGROUND: Patients hospitalized for medical illness are at increased risk of venous thromboembolism (VTE), but the duration of risk is not well understood.
OBJECTIVE: To assess incidence and time course of symptomatic VTE following hospitalization for medical illness in a large, real-world patient population.
DESIGN: Data were extracted from the Thomson Reuters MarketScan(®) Inpatient Drug Link File. PATIENTS: Those hospitalized with cancer, heart failure, severe lung disease, or infectious disease from 2005 to 2008. MEASUREMENTS: The cumulative VTE risk over 180 days after admission was calculated using Kaplan-Meier analysis. VTE hazard was calculated on a daily basis and smoothed through LOESS regression.
RESULTS: The analysis included 11,139 medically ill patients, 46.7% and 8.8% of whom received pharmacological thromboprophylaxis during hospitalization and after discharge, respectively. The mean duration of prophylaxis during hospitalization was 5.0 days. Of the 11,139 patients, 366 (3.3%) experienced a symptomatic VTE event. VTE events were most frequent during days 0-9 (97 events), followed by days 10-19 (82 events). The mean length of hospital stay was 5.3 days, and 56.6% of all VTE events occurred after discharge. VTE hazard peaked at day 8, with 1.05 events per 1000 person-days.
CONCLUSIONS: The time course of VTE in medical patients shows that risk of symptomatic VTE is highest during the first 19 days after hospital admission, and extends into the period after discharge. Future research is warranted to investigate risks and benefits of reducing the incidence of VTE after discharge, including the role of improving thromboprophylaxis practices in the inpatient setting and extending thromboprophylaxis after hospitalization.
Copyright © 2011 Society of Hospital Medicine.

Entities:  

Mesh:

Year:  2011        PMID: 22190427     DOI: 10.1002/jhm.1002

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  41 in total

Review 1.  Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?

Authors:  Majed S Al Yami; Osamah M Alfayez; Sawsan M Kurdi; Razan Alsheikh
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

2.  Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.

Authors:  Holly Guy; Vicki Laskier; Mark Fisher; W Richey Neuman; Iwona Bucior; Steven Deitelzweig; Alexander T Cohen
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

3.  Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.

Authors:  Megan K Yee; Tarek Nafee; Yazan Daaboul; Serge Korjian; Fahad AlKhalfan; Mathieu Kerneis; Cara Wiest; Samuel Z Goldhaber; Adrian F Hernandez; Russell D Hull; Alexander T Cohen; Robert A Harrington; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

4.  Thromboprophylaxis after hospital discharge in acutely ill medical patients: need for trials in patients who are at high risk of venous thrombosis.

Authors:  Banne Nemeth; Willem M Lijfering; Suzanne C Cannegieter
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

5.  Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No.

Authors:  Francesco Marongiu; Doris Barcellona
Journal:  Intern Emerg Med       Date:  2018-03-28       Impact factor: 3.397

Review 6.  COVID-19 associated thromboinflammation of renal capillary: potential mechanisms and treatment.

Authors:  Xiaojing Chen; Chengyuan Yu; Haijiao Jing; Chunxu Wang; Xinyi Zhao; Jinming Zhang; Shuoqi Zhang; Huan Liu; Rujuan Xie; Jialan Shi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

7.  Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study.

Authors:  Jeffrey I Zwicker; Adam Rojan; Federico Campigotto; Nadia Rehman; Renee Funches; Gregory Connolly; Jonathan Webster; Anita Aggarwal; Dalia Mobarek; Charles Faselis; Donna Neuberg; Frederick R Rickles; Ted Wun; Michael B Streiff; Alok A Khorana
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

Review 8.  New Trends in Anticoagulation Therapy.

Authors:  Margaret Smith; Glenn Wakam; Thomas Wakefield; Andrea Obi
Journal:  Surg Clin North Am       Date:  2018-02-03       Impact factor: 2.741

9.  Is there a role for low-dose DOACs as prophylaxis?

Authors:  Alexander T Cohen; Beverley J Hunt
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

10.  The effects of obesity on venous thromboembolism: A review.

Authors:  Genyan Yang; Christine De Staercke; W Craig Hooper
Journal:  Open J Prev Med       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.